The Rotterdam and NIH Criteria: How Polycystic Ovary Syndrome is Diagnosed, and the Global Consensus on First-Line Management

Many wellness influencers and online forums claim that a diagnosis of Polycystic Ovary Syndrome (PCOS) requires the presence of actual cysts on the ovaries, but clinical guidelines state otherwise. The evidence directly contradicts this naming misconception: the "cysts" are actually normal, immature egg follicles that have stalled in development, and under the latest international diagnostic criteria, a patient can be diagnosed with PCOS without any ultrasound evidence of them at all.

"Plenty of women who have PCOS don't have 'polycystic-appearing' ovaries," notes Dr. Erica Wang, a reproductive endocrinologist at Cedars-Sinai. "That's why we use a broader set of criteria for diagnosis." This misunderstanding often delays care for women who experience the metabolic and hormonal symptoms of the condition but assume their clear ultrasounds rule it out.

The definition of PCOS has evolved significantly over the last three decades, shifting how clinicians identify the most common endocrine disorder in reproductive-age women. In 1990, the National Institutes of Health (NIH) established the first formal diagnostic criteria, which required a patient to present with both hyperandrogenism (clinical or biochemical signs of excess male hormones) and ovulatory dysfunction (irregular or absent periods). Crucially, the NIH criteria did not include ovarian morphology, meaning ultrasound findings were entirely excluded from the diagnostic process.[3]

That framework changed in 2003 when experts convened in the Netherlands to establish the Rotterdam criteria, which broadened the definition to capture a wider spectrum of the disorder. The Rotterdam consensus introduced polycystic ovarian morphology (PCOM) as a third potential marker and required that a patient exhibit any two of the three symptoms: ovulatory dysfunction, hyperandrogenism, or PCOM.

By allowing a diagnosis for women who had irregular periods and PCOM but no excess androgens—or excess androgens and PCOM but regular periods—the Rotterdam criteria effectively doubled the recognized prevalence of PCOS from roughly 5 to 8 percent up to 15 percent of reproductive-age women.[3]

In 2023, the International Evidence-based Guideline for the Assessment and Management of PCOS—developed by a network of multidisciplinary experts across 71 countries—reaffirmed the Rotterdam criteria but introduced a major diagnostic update for adults. The new guidelines allow clinicians to use a blood test measuring Anti-Müllerian Hormone (AMH) as a direct alternative to a transvaginal ultrasound for detecting PCOM. Because AMH is produced by the small ovarian follicles, elevated levels serve as a reliable proxy for polycystic morphology, offering a less invasive diagnostic pathway for adult patients.[1][4]

However, the 2023 guidelines draw a strict line regarding adolescent diagnoses. Because irregular menstrual cycles and multi-follicular ovaries are normal phases of pubertal development, the guidelines explicitly prohibit the use of both ultrasound and AMH testing in adolescents. Instead, a PCOS diagnosis in a teenager requires the strict presence of both ovulatory dysfunction and clinical hyperandrogenism, effectively reverting to the narrower NIH criteria for that specific age group to prevent overdiagnosis.[1][4]

Once a diagnosis is established, the global consensus on first-line management prioritizes targeted symptom relief and long-term metabolic health. Lifestyle modifications, including tailored nutrition and exercise, remain the foundational intervention for all PCOS phenotypes. Because a significant portion of women with PCOS exhibit intrinsic insulin resistance and compensatory hyperinsulinemia regardless of their body mass index, addressing metabolic function is critical to preventing long-term complications like type 2 diabetes and cardiovascular disease.[1][4]

For pharmacological management, the 2023 guidelines clarify that combined oral contraceptives (COCs) are the first-line medical treatment for managing irregular menstrual cycles and clinical hyperandrogenism, such as hirsutism and acne. COCs work by directly inhibiting ovarian androgen production and increasing sex hormone-binding globulin, which reduces the availability of free androgens in the bloodstream. However, the guidelines caution that COCs should only be prescribed for these specific symptoms, not as a blanket treatment for all PCOS patients.[2]

When the primary goal is fertility, the pharmacological consensus has definitively shifted. Letrozole, an aromatase inhibitor, is now the recommended first-line treatment for ovulation induction in anovulatory infertile women with PCOS who have no other fertility factors. Clinical trials demonstrated that letrozole yields higher live birth rates and a lower risk of multiple pregnancies compared to clomiphene citrate, which was historically the standard of care.[2]

Metformin continues to play a vital adjunct role, particularly for metabolic indications. While it is less effective than COCs for treating hyperandrogenism, metformin is widely prescribed to improve insulin sensitivity, lipid profiles, and overall metabolic health in PCOS patients. The 2023 guidelines emphasize that PCOS is a lifelong, multi-system condition, urging clinicians to look beyond reproductive symptoms and implement regular cardiovascular and psychological screening to address the diverse burden of the disease.[1][2]